Cargando…

Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are reported to reduce body fat in patients with type 2 diabetes mellitus (T2DM), and SGLT2i-induced weight reduction may help improve comorbid nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the potential benefit of SGLT2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Euh, Won, Lim, Soo, Kim, Jin-Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222919/ https://www.ncbi.nlm.nih.gov/pubmed/34177796 http://dx.doi.org/10.3389/fendo.2021.613389

Ejemplares similares

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
por: Zhang, Enxiang, et al.
Publicado: (2021)

Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
por: Dokmak, Amr, et al.
Publicado: (2019)

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
por: Akuta, Norio, et al.
Publicado: (2017)

Role of extracellular vesicles in nonalcoholic fatty liver disease
por: Jiang, Wei, et al.
Publicado: (2023)

The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Ndakotsu, Andrew, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
por: Yu, Yuetian, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease in University Rugby Football Players
por: Nirengi, Shinsuke, et al.
Publicado: (2018)

The impact of obstructive sleep apnea on nonalcoholic fatty liver disease
por: Tang, Haiying, et al.
Publicado: (2023)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
por: Mandal, Amrendra, et al.
Publicado: (2018)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2022)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
por: Tsankof, Alexandra, et al.
Publicado: (2022)

Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease
por: Jiang, Yuanye, et al.
Publicado: (2023)

Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study
por: Li, Ran, et al.
Publicado: (2023)

Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
por: Das, Chandan, et al.
Publicado: (2021)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2023)

Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
por: Takahashi, Hirokazu, et al.
Publicado: (2018)

Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
por: Lyu, Jingting, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2018)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Mitra, Asis
Publicado: (2020)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
por: Yabiku, Koichi
Publicado: (2021)

Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease
por: Zhong, Fang, et al.
Publicado: (2021)

Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity
por: Zhou, Xuelian, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese
por: Jiang, Li-Peng, et al.
Publicado: (2022)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
por: Takeshita, Yumie, et al.
Publicado: (2020)

Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
por: Xia, Chengdong, et al.
Publicado: (2023)

Cardiac abnormalities in patients with nonalcoholic fatty liver disease
por: Mota, Adriana Hendler, et al.
Publicado: (2022)

Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
por: Cho, Eun-Ju, et al.
Publicado: (2021)

The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
por: Goto, Ryo, et al.
Publicado: (2019)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pbqvqglufbofm1gvsm01pje2qc